Subtopic Deep Dive
Sorafenib and Tyrosine Kinase Inhibitors
Research Guide
What is Sorafenib and Tyrosine Kinase Inhibitors?
Sorafenib and tyrosine kinase inhibitors (TKIs) are multikinase inhibitors including sorafenib, lenvatinib, regorafenib, and cabozantinib used as systemic therapies for advanced hepatocellular carcinoma (HCC), improving progression-free survival and overall survival.
Sorafenib established first-line therapy for advanced HCC in the SHARP trial, extending median survival by nearly 3 months over placebo (Llovet et al., 2008; 12,748 citations). Regorafenib and cabozantinib serve as second-line options post-sorafenib progression (Bruix et al., 2016; Abou-Alfa et al., 2018). Over 50 key papers detail TKI efficacy, biomarkers, and sequencing with immunotherapies.
Why It Matters
TKIs transformed HCC from an unmet need to a treatable advanced cancer, with sorafenib approval in 2007 enabling systemic therapy standards (Llovet et al., 2008). Regorafenib improved survival in sorafenib-refractory patients by 2.8 months in the RESORCE trial (Bruix et al., 2016). Cabozantinib extended median survival to 10.2 months versus 8.0 months with placebo (Abou-Alfa et al., 2018). Guidelines by AASLD integrate TKIs with liver function assessments like ALBI grade for personalized treatment (Heimbach et al., 2017; Johnson et al., 2014).
Key Research Challenges
High Adverse Event Rates
TKIs like sorafenib cause hand-foot skin reaction and diarrhea in over 20% of patients, limiting tolerability (Llovet et al., 2008). Regorafenib elevates hypertension and fatigue risks post-sorafenib (Bruix et al., 2016). Balancing efficacy against toxicity requires biomarkers for patient selection.
Response Assessment Difficulties
Standard RECIST underestimates HCC response due to viable tumor necrosis, necessitating mRECIST criteria (Lencioni and Llovet, 2010; 4,157 citations). Trials use time-to-progression as surrogate endpoints amid concurrent liver disease (Llovet et al., 2008). Accurate imaging endpoints remain critical for TKI evaluation.
Optimal Sequencing Strategies
Post-sorafenib progression demands second-line TKIs like regorafenib or cabozantinib, but immunotherapy combinations like atezolizumab-bevacizumab outperform sorafenib (Finn et al., 2020). Liver function via ALBI grade guides sequencing to avoid decompensation (Johnson et al., 2014). Biomarker-driven orders lack validation.
Essential Papers
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · 2008 · New England Journal of Medicine · 12.7K citations
In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given place...
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · 2020 · New England Journal of Medicine · 6.7K citations
In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. (Funded by F. Hoffma...
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva et al. · 2021 · Nature Reviews Disease Primers · 6.0K citations
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin et al. · 2018 · Hepatology · 4.4K citations
Marrero, Jorge A.; Kulik, Laura M.; Sirlin, Claude B.; Zhu, Andrew X.; Finn, Richard S.; Abecassis, Michael M.; Roberts, Lewis R.; Heimbach, Julie K. Author Information
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni, Josep M. Llovet · 2010 · Seminars in Liver Disease · 4.2K citations
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rat...
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura Kulik, Richard S. Finn et al. · 2017 · Hepatology · 4.1K citations
Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bris...
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix, Shukui Qin, Philippe Merle et al. · 2016 · The Lancet · 3.6K citations
Reading Guide
Foundational Papers
Start with Llovet et al. (2008) for sorafenib's landmark survival data establishing TKIs as standard; follow with Lencioni and Llovet (2010) for mRECIST essential to interpret TKI trial responses; then Johnson et al. (2014) for ALBI grading to contextualize liver function in TKI eligibility.
Recent Advances
Finn et al. (2020) shows immunotherapy superiority over sorafenib; Abou-Alfa et al. (2018) details cabozantinib second-line benefits; Llovet et al. (2021) reviews TKI integration in modern HCC management.
Core Methods
Multikinase inhibition of Raf/VEGF/PDGFR pathways; phase 3 RCTs with OS/PFS endpoints via mRECIST; ALBI grade for liver reserve; sequencing post-progression assessed by hazard ratios.
How PapersFlow Helps You Research Sorafenib and Tyrosine Kinase Inhibitors
Discover & Search
Research Agent uses searchPapers with query 'sorafenib regorafenib HCC phase 3' to retrieve Llovet et al. (2008) and Bruix et al. (2016), then citationGraph maps 12,748 sorafenib citations to second-line trials, while findSimilarPapers links to Abou-Alfa et al. (2018) cabozantinib results.
Analyze & Verify
Analysis Agent applies readPaperContent to extract SHARP trial survival data from Llovet et al. (2008), verifies response claims via verifyResponse (CoVe) against mRECIST standards (Lencioni and Llovet, 2010), and runs PythonAnalysis with pandas to compute hazard ratios from RESORCE trial tables (Bruix et al., 2016), graded by GRADE for moderate evidence quality.
Synthesize & Write
Synthesis Agent detects gaps in TKI biomarker research post-Finn et al. (2020) immunotherapy shift and flags contradictions in adverse event rates across trials; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 10+ TKI papers, and latexCompile for a review manuscript, with exportMermaid for survival curve flowcharts.
Use Cases
"Extract survival data from sorafenib and regorafenib HCC trials and plot Kaplan-Meier curves"
Research Agent → searchPapers('sorafenib regorafenib HCC survival') → Analysis Agent → readPaperContent(Llovet 2008, Bruix 2016) → runPythonAnalysis(pandas/matplotlib for HR computation and curve plotting) → researcher gets CSV-exported survival stats and GRADE-verified plots.
"Write a LaTeX review section comparing TKI efficacy in advanced HCC with AASLD guidelines"
Research Agent → citationGraph(AASLD guidelines) → Synthesis Agent → gap detection(TKI sequencing) → Writing Agent → latexEditText(draft section) → latexSyncCitations(Heimbach 2017, Llovet 2008) → latexCompile → researcher gets compiled PDF with synced references.
"Find open-source code for mRECIST HCC tumor response analysis from papers"
Research Agent → searchPapers('mRECIST HCC code') → paperExtractUrls(Lencioni 2010) → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python scripts for automated response scoring linked to TKI trial imaging data.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TKI papers: searchPapers(sorafenib/resistance) → citationGraph → DeepScan(7-step verification with CoVe on survival endpoints from Llovet 2008). Theorizer generates hypotheses on ALBI-stratified TKI sequencing: readPaperContent(Johnson 2014) → synthesis → theory export. DeepScan analyzes RESORCE adverse events with runPythonAnalysis for statistical significance (Bruix 2016).
Frequently Asked Questions
What is the definition of Sorafenib and TKIs in HCC?
Multikinase inhibitors like sorafenib target VEGF/PDGF receptors to extend survival in advanced HCC by 3 months over placebo (Llovet et al., 2008).
What are key methods for TKI response assessment?
mRECIST measures viable tumor enhancement to capture necrosis missed by RECIST, used in SHARP and RESORCE trials (Lencioni and Llovet, 2010).
What are key papers on TKIs in HCC?
Llovet et al. (2008) on sorafenib (12,748 citations), Bruix et al. (2016) on regorafenib, Abou-Alfa et al. (2018) on cabozantinib.
What are open problems in TKI research?
Biomarker prediction of response/resistance, optimal sequencing with immunotherapies, and toxicity mitigation in Child-Pugh B patients remain unsolved (Finn et al., 2020; Johnson et al., 2014).
Research Hepatocellular Carcinoma Treatment and Prognosis with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Sorafenib and Tyrosine Kinase Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.